Dr. Tammy E. Roque, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in Shreveport (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 682
Licensed in Texas since 1990, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: Louisiana State University School of Medicine in Shreveport
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license H8588 (first issued 1990; texas retired)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 682
- Services billed
- 224,987
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 14,280 | 20 |
| Injection, pembrolizumab, 1 mg | 7,300 | 21 |
| Injection, iron sucrose, 1 mg | 5,600 | 20 |
| Injection, oxaliplatin, 0.5 mg | 5,200 | 11 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2,645 | 37 |
| Injection, fosaprepitant, 1 mg | 2,400 | 11 |
| Injection, denosumab, 1 mg | 1,620 | 14 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,044 | 270 |
| Insertion of needle into vein for collection of blood sample | 1,036 | 260 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,010 | 50 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Sherman, TX | 127 |
| Letrozole Other prescribers in Sherman, TX | 116 |
| Acyclovir Other prescribers in Sherman, TX | 111 |
| Gabapentin Other prescribers in Sherman, TX | 92 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Sherman, TX | 86 |
| Pantoprazole Sodium Other prescribers in Sherman, TX | 63 |
| Dexamethasone Other prescribers in Sherman, TX | 62 |
| Ondansetron Hcl Other prescribers in Sherman, TX | 47 |
| Fentanyl Other prescribers in Sherman, TX | 46 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Sherman, TX | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $21.48 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $21.48 |
|---|
| Food and Beverage | $21.48 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $3,242 in research payments for these studies, mostly to the institutions running them.
- A phase 3, randomized, double-blind, placebo-controlled, multicenter s
GlaxoSmithKline, LLC. - Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT01838512
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.